Artivion, Inc.

Valuation Analysis

About the Company

Artivion, Inc. en bref

Artivion, Inc. (AORT) is currently trading at 18,47 € with a market capitalization of 897 M €. The trailing P/E ratio stands at 84.76x, with a forward P/E of 28.64x. The 52-week range spans from 16,70 € to 42,06 €; the current price is 56.1% below the yearly high. Year-over-year revenue growth stands at +17.5%. The net profit margin stands at 2.55%.

💰 Dividende

Artivion, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

8 analystes évaluent Artivion, Inc. (AORT) au consensus : Achat Fort. L'objectif de cours moyen est de 36,61 €, soit un potentiel de +98.21% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 31,38 € à 41,84 €.

Artivion, Inc. : la thèse d'investissement en détail

Artivion, Inc. (AORT) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 17.5% pace year-over-year, suggesting the business model continues to find new customers and pricing power. With a gross margin near 64.55%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Strong Buy with an average price target implying roughly 98.21% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

With a net margin of just 2.55%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss. A trailing P/E above 50 combined with revenue growth below 20% is a dangerous combination — the market is paying a steep growth multiple for what is, by the data, only moderately fast expansion. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valorisation en contexte

At a PEG of 643.75, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here.

À surveiller

• The forward P/E of 28.64x is meaningfully below the trailing 84.76x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 98.21% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to market-like volatility.

Trading Data

Related Stocks in the Same Sector

Where can I buy Artivion, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.